tetano
Editor, Senior Moderator
J Ophthalmol
. 2021 Dec 8;2021:2678706.
doi: 10.1155/2021/2678706. eCollection 2021.
Symptoms of Dry Eye Disease in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19)
Yan Wang[SUP] 1 [/SUP], Sen Yang[SUP] 2 [/SUP], Yue Zhang[SUP] 3 [/SUP], Xin Zhang[SUP] 4 [/SUP], Yaping Jiang[SUP] 4 [/SUP], Xixi Wang[SUP] 1 [/SUP], Pengxiang Zheng[SUP] 5 [/SUP], Yihui Chen[SUP] 4 [/SUP]
Affiliations
Abstract
Background: We aimed to investigate the symptoms of the dry eye disease (DED) of hospitalized patients with coronavirus disease 2019 (COVID-19).
Methods: This cross-sectional, observational study analysis included 91 hospitalized patients with confirmed COVID-19 in Wuhan, China. The Ocular Surface Disease Index (OSDI) and the five-item Dry Eye Questionnaire (DEQ-5) were used to assess the severity of DED symptoms in the patients, and the analysis of variance was used to determine the factors associated with DED.
Results: A total of 42 patients consented to complete the investigation (response rate 46.15%). There were 26 (61.90%) patients who were diagnosed with DED symptoms by OSDI, and there were 28 (66.67%) patients with DED symptoms who were diagnosed by DEQ-5 score. For the biochemical tests, the patients with DED symptoms had lower aspartate aminotransferase (AST) levels compared to those with no DED symptoms (20.86 vs. 42.14, p=0.04). Further analysis showed that a previous history of cardiac or stroke disease (p=0.02) and typical symptoms of muscle soreness (p=0.03) were significantly different among the four DED symptoms groups on the basis of OSDI scores. The contributing factors of OSDI were mainly focused on visual function and environmental triggers.
Conclusion: The incidence of DED symptoms is higher in hospitalized patients with COVID-19. The serum AST levels, history of cardiac or stroke disease, and the typical symptoms of muscle soreness may be the main impact factors on DED symptoms. We also need to pay more attention to the visual function and environmental triggers of hospitalized patients with COVID-19.
. 2021 Dec 8;2021:2678706.
doi: 10.1155/2021/2678706. eCollection 2021.
Symptoms of Dry Eye Disease in Hospitalized Patients with Coronavirus Disease 2019 (COVID-19)
Yan Wang[SUP] 1 [/SUP], Sen Yang[SUP] 2 [/SUP], Yue Zhang[SUP] 3 [/SUP], Xin Zhang[SUP] 4 [/SUP], Yaping Jiang[SUP] 4 [/SUP], Xixi Wang[SUP] 1 [/SUP], Pengxiang Zheng[SUP] 5 [/SUP], Yihui Chen[SUP] 4 [/SUP]
Affiliations
- PMID: 34912574
- PMCID: PMC8668290
- DOI: 10.1155/2021/2678706
Abstract
Background: We aimed to investigate the symptoms of the dry eye disease (DED) of hospitalized patients with coronavirus disease 2019 (COVID-19).
Methods: This cross-sectional, observational study analysis included 91 hospitalized patients with confirmed COVID-19 in Wuhan, China. The Ocular Surface Disease Index (OSDI) and the five-item Dry Eye Questionnaire (DEQ-5) were used to assess the severity of DED symptoms in the patients, and the analysis of variance was used to determine the factors associated with DED.
Results: A total of 42 patients consented to complete the investigation (response rate 46.15%). There were 26 (61.90%) patients who were diagnosed with DED symptoms by OSDI, and there were 28 (66.67%) patients with DED symptoms who were diagnosed by DEQ-5 score. For the biochemical tests, the patients with DED symptoms had lower aspartate aminotransferase (AST) levels compared to those with no DED symptoms (20.86 vs. 42.14, p=0.04). Further analysis showed that a previous history of cardiac or stroke disease (p=0.02) and typical symptoms of muscle soreness (p=0.03) were significantly different among the four DED symptoms groups on the basis of OSDI scores. The contributing factors of OSDI were mainly focused on visual function and environmental triggers.
Conclusion: The incidence of DED symptoms is higher in hospitalized patients with COVID-19. The serum AST levels, history of cardiac or stroke disease, and the typical symptoms of muscle soreness may be the main impact factors on DED symptoms. We also need to pay more attention to the visual function and environmental triggers of hospitalized patients with COVID-19.